| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2694 | In-1166 | Novel ALK5 inhibitor |
|
| DCC2695 | Incb018424 Racemic | Janus-associated kinase (JAK) inhibitor |
|
| DCC2696 | Incb059872 Tosylate | Novel potent and selective lysine-specific demethylase 1 (LSD1) inhibitor |
|
| DCC2697 | Ind-07 | Novel selective Mtb-DHFR inhibitor as an antimycobacterial agent |
|
| DCC2698 | Ind31119 | Novel selective inhibitor of PfHsp90, bypassing its highly similar human orthologs |
|
| DCC2699 | Ind45193 | Antiprion agent, reducing PrP(Sc) levels in dividing and stationary-phase cells |
|
| DCC2700 | Indazole-cl | Selective estrogen receptor modifier (SERM), being a selective ERß agonist |
|
| DCC2701 | Indeloxazine Hydrochloride | Antidepressant and cerebral activator, acting as a serotonin releasing agent, norepinephrine reuptake inhibitor, and NMDA receptor antagonist, enhancing acetylcholine release via activation of the 5-HT4 receptor |
|
| DCC2702 | Indimitecan Hydrochloride | Topoisomerase I (Top1) inhibitor |
|
| DCC2703 | Indobufen | Platelet aggregation inhibitor acting as a reversible Cyclooxygenase>cyclooxygenase inhibitor |
|
| DCC2704 | Indole-3-lactic Acid | Metabolite of tryptophan, reducing the interleukin-8 (IL-8) response after IL-1β stimulus, interacting with the transcription factor aryl hydrocarbon receptor (AHR) and preventing transcription of the inflammatory cytokine IL-8, being anti-inflammatory in |
|
| DCC2705 | Indolmycin | Natural antibiotic, selectively inhibiting bacterial tryptophanyl-tRNA synthetase (TrpRS) |
|
| DCC2706 | Indoluidin D | Novel inhibitor of dihydroorotate dehydrogenase (DHODH), promoting myeloid differentiation and inhibiting the proliferation of acute promyelocytic leukemia HL-60 cells, also suppressing cell growth in various other types of cancer cells |
|
| DCC2707 | Indotecan Hydrochloride | Topoisomerase I (Top1) inhibitor |
|
| DCC2708 | Indoxam | Novel sPLA2 inhibitor, suppressing murine endotoxic shock and LDL modification, blocking binding to the M-type receptor |
|
| DCC2709 | Indoxyl Sulfate | Metabolite of tryptophan, showing adverse effects on bones and the central nervous system, having been most frequently implicated as a contributor to renal disease progression and vascular disease |
|
| DCC2710 | Infraluciferin | NIR emitting firefly luciferin analogue |
|
| DCC2711 | Ingavirin | Novel inhibitor of the influenza virus reproduction, inhubiting the formation of the virus specific hemagglutinin |
|
| DCC2712 | inh-32 | Novel inhibitor of Ark1, the fission yeast member of the conserved Aurora kinase family |
|
| DCC2713 | Inhib1x | Novel dual inhibitor of MAPKAPK5 and MAPKAPK2 |
|
| DCC2714 | Inhibitor R1 | Novel Potent Inhibitor of Microbiome ß-Glucuronidases |
|
| DCC2715 | Inhibitor R3 | Novel Potent Inhibitor of Microbiome ß-Glucuronidases |
|
| DCC2716 | Inos-in-10 | Novel selective inhibitor of the iNOS, without affecting the eNOS isoform |
|
| DCC2717 | Inos-in-18 | Novel Potent and Selective Inducible Nitric Oxide Synthase (iNOS) Inhibitor (IC50 = 74 nM) with high BBB permeability (Pe = 19.1 × 10-6 cm/s) for Parkinson's Disease |
|
| DCC2718 | Inos-in-d27 | Novel Potent and Orally Active Inducible Nitric Oxide Synthase (iNOS) Dimerization Inhibitor with Efficacy in Rheumatoid Arthritis Mouse Model |
|
| DCC2719 | Inp1750 | Novel putative inhibitor of type III secretion (T3S) in the Gram-negative pathogen Yersinia pseudotuberculosis and Chlamydia trachomatis |
|
| DCC2720 | Ins015_037 | Novel potent inhibitor of DDR1 tyrosine kinase |
|
| DCC2721 | Ins3-54-a26 | Novel inhibitor of the DNA-binding domain (DBD) of STAT3, suppressing tumor growth, metastasis and STAT3 target gene expression in vivo |
|
| DCC2722 | Ins48823 | Activator of the P2Y6 receptor in bone, increasing survival of osteoclasts |
|
| DCC2723 | Int2-31 | Blocker of the interaction of FAK and IGF-1R; Antagonist of the phosphorylation of tumor AKT |
|
